AI Engines For more Details: Perplexity Kagi Labs You
Management of Vitamin D Deficiency: Alfacalcidol is used in the management of vitamin D deficiency or insufficiency, which can lead to abnormalities in calcium and phosphate metabolism, as well as bone disorders such as osteoporosis or osteomalacia.
Calcium and Phosphate Regulation: Alfacalcidol plays a crucial role in the regulation of calcium and phosphate levels in the body. It enhances the absorption of calcium and phosphate from the intestine, promotes the reabsorption of calcium from the kidneys, and stimulates bone resorption, thereby maintaining calcium and phosphate homeostasis.
Treatment of Osteoporosis: Alfacalcidol may be used as part of a comprehensive treatment regimen for osteoporosis, a condition characterized by reduced bone density and increased risk of fractures. By promoting calcium absorption and bone mineralization, alfacalcidol helps improve bone strength and reduce fracture risk in patients with osteoporosis.
Renal Osteodystrophy: Alfacalcidol is used in the management of renal osteodystrophy, a bone disorder that occurs in patients with chronic kidney disease (CKD) due to abnormalities in calcium and phosphate metabolism. Alfacalcidol helps regulate calcium and phosphate levels and prevent secondary hyperparathyroidism and renal bone disease in patients with CKD.
Hyperparathyroidism: Alfacalcidol may be used in the management of secondary hyperparathyroidism, a condition characterized by excessive secretion of parathyroid hormone (PTH) due to hypocalcemia or vitamin D deficiency. By increasing intestinal calcium absorption and suppressing PTH secretion, alfacalcidol helps normalize calcium and phosphate levels and reduce hyperparathyroidism symptoms.
Psoriasis: Alfacalcidol has been investigated for its potential therapeutic effects in the treatment of psoriasis, a chronic inflammatory skin disorder. Vitamin D analogs such as alfacalcidol may help regulate keratinocyte proliferation and differentiation, leading to improvement in psoriatic lesions.
Parathyroid Hormone (PTH) Suppression: Alfacalcidol suppresses the secretion of parathyroid hormone (PTH) by directly inhibiting parathyroid gland function. This can help reduce PTH-mediated bone resorption and prevent the development of hyperparathyroidism or bone complications in patients with CKD or other conditions.
Calcium and Phosphate Monitoring: Patients receiving alfacalcidol therapy should undergo regular monitoring of serum calcium, phosphate, and PTH levels to assess treatment response and prevent the development of hypercalcemia or hyperphosphatemia.
Side Effects: Common side effects of alfacalcidol may include hypercalcemia (elevated blood calcium levels), hyperphosphatemia (elevated blood phosphate levels), gastrointestinal symptoms such as nausea or vomiting, and renal impairment. Patients should be monitored for signs of hypercalcemia or other adverse effects during alfacalcidol therapy.
Contraindications: Alfacalcidol is contraindicated in patients with hypercalcemia, hyperphosphatemia, vitamin D toxicity, or hypersensitivity to the drug or its components. It should be used with caution in patients with impaired renal function, as dose adjustments may be necessary to prevent the development of hypercalcemia or other complications.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 2 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Bacteroidaceae | family | Decreases |
| 2 | 0 | Akkermansia | genus | Decreases |
| 1 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 2 | environmental samples | no rank | Decreases |
| 0 | 2 | unclassified Akkermansia | no rank | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Bacteroides | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 1 | 1 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 1 | 1 | Bacteroides fragilis | species | Decreases |
| 1 | 1 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 0 | 2 | Akkermansia massiliensis | species | Decreases |
| 0 | 2 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 1 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 0 | 1 | Bacteroides acidifaciens | species | Decreases |
| 0 | 1 | Bacteroides caecigallinarum | species | Decreases |
| 0 | 1 | Bacteroides caecimuri | species | Decreases |
| 0 | 1 | Bacteroides chinchillae | species | Decreases |
| 0 | 1 | Bacteroides clarus | species | Decreases |
| 0 | 1 | Bacteroides congonensis | species | Decreases |
| 0 | 1 | Bacteroides cutis | species | Decreases |
| 0 | 1 | Bacteroides denticanum | species | Decreases |
| 0 | 1 | Bacteroides difficilis | species | Decreases |
| 0 | 1 | Bacteroides faecalis | species | Decreases |
| 0 | 1 | Bacteroides faecichinchillae | species | Decreases |
| 0 | 1 | Bacteroides finegoldii | species | Decreases |
| 0 | 1 | Bacteroides fluxus | species | Decreases |
| 0 | 1 | Bacteroides galacturonicus | species | Decreases |
| 0 | 1 | Bacteroides gallinaceum | species | Decreases |
| 0 | 1 | Bacteroides gallinarum | species | Decreases |
| 0 | 1 | Bacteroides graminisolvens | species | Decreases |
| 0 | 1 | Bacteroides ihuae | species | Decreases |
| 0 | 1 | Bacteroides ilei | species | Decreases |
| 0 | 1 | Bacteroides koreensis | species | Decreases |
| 0 | 1 | Bacteroides kribbi | species | Decreases |
| 0 | 1 | Bacteroides luti | species | Decreases |
| 0 | 1 | Bacteroides mediterraneensis | species | Decreases |
| 0 | 1 | Bacteroides muris (ex Fokt et al. 2023) | species | Decreases |
| 0 | 1 | Bacteroides ndongoniae | species | Decreases |
| 0 | 1 | Bacteroides oleiciplenus | species | Decreases |
| 0 | 1 | Bacteroides parvus | species | Decreases |
| 0 | 1 | Bacteroides propionicifaciens | species | Decreases |
| 0 | 1 | Bacteroides propionicigenes | species | Decreases |
| 0 | 1 | Bacteroides pyogenes | species | Decreases |
| 0 | 1 | Bacteroides reticulotermitis | species | Decreases |
| 0 | 1 | Bacteroides rhinocerotis | species | Decreases |
| 0 | 1 | Bacteroides rodentium | species | Decreases |
| 0 | 1 | Bacteroides sp | species | Decreases |
| 0 | 1 | Bacteroides sp. C13EG172 | species | Decreases |
| 0 | 1 | Bacteroides stercorirosoris | species | Decreases |
| 0 | 1 | Bacteroides timonensis | species | Decreases |
| 0 | 1 | Candidatus Bacteroides intestinigallinarum | species | Decreases |
| 1 | 1 | Bacteroides ovatus | species | Decreases |
| 0 | 1 | Bacteroides luhongzhouii | species | Decreases |
| 0 | 1 | Bacteroides xylanisolvens | species | Decreases |
| 0 | 1 | Bacteroides thetaiotaomicron | species | Decreases |
| 0 | 1 | Bacteroides caecimuris | species | Decreases |
| 0 | 1 | Bacteroides humanifaecis | species | Decreases |
| 0 | 1 | Bacteroides faecium | species | Decreases |
| 0 | 1 | Bacteroides salyersiae | species | Decreases |
| 0 | 1 | Bacteroides faecis | species | Decreases |
| 0 | 1 | Bacteroides helcogenes | species | Decreases |
| 0 | 1 | Bacteroides eggerthii | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 0 | 1 | Bacteroides intestinalis | species | Decreases |
| 0 | 1 | Bacteroides cellulosilyticus | species | Decreases |
| 0 | 1 | Bacteroides stercoris | species | Decreases |
| 0 | 2 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Bacteroides nordii | species | Decreases |
| 0 | 1 | Bacteroides zhangwenhongii | species | Decreases |
| 0 | 1 | Bacteroides heparinolyticus | species | Decreases |
| 0 | 1 | Bacteroides coprosuis | species | Decreases |
| 0 | 1 | Bacteroides zoogleoformans | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
| Acne | 1 | 0.9 | 0.11 |
| ADHD | 4 | 0.9 | 3.44 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.9 | 2.8 | 0.04 |
| Allergies | 7.3 | 5 | 0.46 |
| Allergy to milk products | 1.8 | 1.1 | 0.64 |
| Alopecia (Hair Loss) | 1.5 | 1.5 | |
| Alzheimer's disease | 6.1 | 6.8 | -0.11 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.2 | 1.1 | 1.91 |
| Ankylosing spondylitis | 4.3 | 1.3 | 2.31 |
| Anorexia Nervosa | 1.3 | 2.8 | -1.15 |
| Antiphospholipid syndrome (APS) | 1.1 | 0.3 | 2.67 |
| Asthma | 5.5 | 3.5 | 0.57 |
| Atherosclerosis | 1.3 | 3.2 | -1.46 |
| Atrial fibrillation | 3.6 | 2.6 | 0.38 |
| Autism | 10.8 | 9.1 | 0.19 |
| Autoimmune Disease | 0.6 | 1 | -0.67 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.4 | -0.4 | |
| Biofilm | 1.8 | 1.8 | |
| Bipolar Disorder | 1.6 | 1.4 | 0.14 |
| Brain Trauma | 0.9 | 1.2 | -0.33 |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.6 | 2.5 | -3.17 |
| Carcinoma | 3.6 | 2.4 | 0.5 |
| Celiac Disease | 3.1 | 4 | -0.29 |
| Cerebral Palsy | 1.9 | 1.1 | 0.73 |
| Chronic Fatigue Syndrome | 3.9 | 7.1 | -0.82 |
| Chronic Kidney Disease | 4.4 | 3.4 | 0.29 |
| Chronic Lyme | 0.6 | 0.9 | -0.5 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.1 | 1.7 | 0.24 |
| Chronic Urticaria (Hives) | 0.8 | 1.5 | -0.88 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1 | -0.43 |
| Cognitive Function | 3.7 | 1.6 | 1.31 |
| Colorectal Cancer | 9.7 | 3.3 | 1.94 |
| Constipation | 1.6 | 1.7 | -0.06 |
| Coronary artery disease | 1.5 | 2.9 | -0.93 |
| COVID-19 | 9.3 | 12.8 | -0.38 |
| Crohn's Disease | 7.3 | 5.8 | 0.26 |
| Cushing's Syndrome (hypercortisolism) | 1 | -1 | |
| cystic fibrosis | 2 | -2 | |
| deep vein thrombosis | 1.7 | 1.2 | 0.42 |
| Denture Wearers Oral Shifts | 1.2 | 1.2 | |
| Depression | 10.7 | 10.6 | 0.01 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.7 | 2.9 | -0.71 |
| Endometriosis | 2.4 | 1.7 | 0.41 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 2.8 | 2.8 | 0 |
| erectile dysfunction | 1.8 | 0.3 | 5 |
| Fibromyalgia | 3.6 | 3.4 | 0.06 |
| Functional constipation / chronic idiopathic constipation | 5 | 4.1 | 0.22 |
| gallstone disease (gsd) | 2.6 | 1.3 | 1 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.3 | 1.2 | 0.08 |
| Generalized anxiety disorder | 2.4 | 3 | -0.25 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.1 | 1.2 | 0.75 |
| Graves' disease | 1.7 | 3.4 | -1 |
| Gulf War Syndrome | 1.2 | 1.8 | -0.5 |
| Halitosis | 1 | 0.3 | 2.33 |
| Hashimoto's thyroiditis | 3.6 | 2.3 | 0.57 |
| Heart Failure | 3.1 | 2.6 | 0.19 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 1.3 | 0.3 | 3.33 |
| High Histamine/low DAO | 1.3 | 0.3 | 3.33 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.6 | -0.2 |
| hyperglycemia | 1.5 | 2.3 | -0.53 |
| Hyperlipidemia (High Blood Fats) | 1.3 | 0.3 | 3.33 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.9 | 5.3 | -0.08 |
| Hypothyroidism | 0.4 | 1 | -1.5 |
| Hypoxia | 3.2 | 0.9 | 2.56 |
| IgA nephropathy (IgAN) | 1.4 | 3.8 | -1.71 |
| Inflammatory Bowel Disease | 8.1 | 9.9 | -0.22 |
| Insomnia | 2.6 | 3.7 | -0.42 |
| Intelligence | 1.2 | 0.6 | 1 |
| Intracranial aneurysms | 1 | 0.9 | 0.11 |
| Irritable Bowel Syndrome | 7 | 5.4 | 0.3 |
| ischemic stroke | 3.1 | 1.2 | 1.58 |
| Liver Cirrhosis | 6.8 | 4.8 | 0.42 |
| Long COVID | 7.1 | 7.5 | -0.06 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.5 | 1.3 | -1.6 |
| Mast Cell Issues / mastitis | 0.3 | 0.6 | -1 |
| ME/CFS with IBS | 0.8 | 2.5 | -2.13 |
| ME/CFS without IBS | 1.7 | 2.3 | -0.35 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.6 | 1 | 0.6 |
| Metabolic Syndrome | 7.3 | 8.4 | -0.15 |
| Mood Disorders | 11 | 8.5 | 0.29 |
| multiple chemical sensitivity [MCS] | 1.6 | 0.1 | 15 |
| Multiple Sclerosis | 7.5 | 5.8 | 0.29 |
| Multiple system atrophy (MSA) | 2.2 | 0.4 | 4.5 |
| myasthenia gravis | 0.3 | 0.7 | -1.33 |
| neuropathic pain | 0.3 | 3.5 | -10.67 |
| Neuropathy (all types) | 1.1 | 2.1 | -0.91 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.3 | 5.6 | -0.3 |
| NonCeliac Gluten Sensitivity | 2 | 0.7 | 1.86 |
| Obesity | 11.1 | 9 | 0.23 |
| obsessive-compulsive disorder | 4.3 | 4.9 | -0.14 |
| Osteoarthritis | 2.5 | 1.4 | 0.79 |
| Osteoporosis | 1.8 | 2.3 | -0.28 |
| pancreatic cancer | 0.9 | 0.7 | 0.29 |
| Parkinson's Disease | 9.2 | 7.2 | 0.28 |
| Polycystic ovary syndrome | 6 | 3.1 | 0.94 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.1 | 0.09 |
| Primary sclerosing cholangitis | 2.5 | 2.7 | -0.08 |
| Psoriasis | 3.2 | 3.9 | -0.22 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.9 | 4.5 | 0.76 |
| Rosacea | 0.9 | 1 | -0.11 |
| Schizophrenia | 6.8 | 3.3 | 1.06 |
| scoliosis | 0.3 | 0.3 | 0 |
| Sjögren syndrome | 2.3 | 3 | -0.3 |
| Sleep Apnea | 1.6 | 1.6 | 0 |
| Slow gastric motility / Gastroparesis | 0.7 | 0.3 | 1.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.5 | 0.6 | 1.5 |
| Stress / posttraumatic stress disorder | 2.9 | 3.3 | -0.14 |
| Systemic Lupus Erythematosus | 4.1 | 1.9 | 1.16 |
| Tic Disorder | 1.2 | 1.8 | -0.5 |
| Tourette syndrome | 1.3 | 0.4 | 2.25 |
| Type 1 Diabetes | 4.5 | 4.2 | 0.07 |
| Type 2 Diabetes | 8.3 | 7.5 | 0.11 |
| Ulcerative colitis | 5.6 | 7.4 | -0.32 |
| Unhealthy Ageing | 5.5 | 2.9 | 0.9 |
| Vitiligo | 2 | 2 | 0 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
